NASDAQ$XXII

22nd Century Group Inc. · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

22nd Century Group's first quarter results for 2021 were reported with a net sales revenue of $6.8 million and a net loss of $5.0 million.

22nd Century Group reported first quarter 2021 financial results, with net sales revenue of $6.8 million and a net loss of $5.0 million. The company is focused on securing FDA authorization for VLN® and advancing its hemp/cannabis business.

  • Net sales revenue for the first quarter of 2021 was $6.8 million, comparable to $7.1 million in the first quarter of 2020.
  • Gross profit for the first quarter of 2021 improved to $647 thousand.
  • Net loss for the first quarter of 2021 was $5.0 million, compared to $4.0 million in the same quarter last year, driven by investment in anticipation of 22nd Century’s expected MRTP designation of VLN®.
  • Cash, cash equivalents, and short-term investment securities totaled $30.9 million at the end of the first quarter of 2021.

Headline financials

Total Revenue

$6.81M

Previous: $7.06M-3.6%
EPS (adj)

-$7.20

Previous: -$7.20+0.0%
Adjusted EBITDA

-$4.4M

No prior period
Capital Expenditures

-$100K

Previous: -$8K-1150.0%
Free Cash Flow

-$5.13M

Previous: -$4.04M-27.1%
Net Income

-$5.03M

Previous: -$4.03M-24.9%
Operating Income

-$5.17M

Previous: -$4.14M-24.8%
Gross Profit

-$6.16M

Previous: $287K-2246.0%
Cash & Equivalents

$30.9M

Previous: $719K+4197.6%
Total Assets

$59.7M

Previous: $64.5M-7.4%
Stock-Based Comp

$507K

No prior period

Revenue & EPS history

22nd Century Group · Revenue · Quarterly

$6.81M

Q1 2021-3.6%vs Q1 2020
Beat estimate in 7 of 11 quarters(64%)
ActualEstimate

Forward guidance

22nd Century Group remains focused on obtaining FDA authorization for VLN® and is prepared to launch the product commercially within 90 days of approval.

Tailwinds

  • Company remains focused on securing FDA authorization for VLN®.
  • Company is fully prepared to execute a commercial product launch and will seek licensing and partnership initiatives within 90 days of MRTP designation.
  • Company will support and advance the FDA’s plan to require all cigarettes sold in the U.S. be made “minimally or non-addictive”.
  • Company continues to target the upstream segment of the cannabinoid value chain.
  • Company will maintain diligent financial execution, efficient operating structure, and balance sheet strength to support its growth initiatives.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-2.9%

Avg return

Earnings day

-3.9%

Avg return

5 days after

-7.7%

Avg return

30 days after

32%

19 / 59 earnings

Positive

+37.4%

Q4 2020

Best reaction

-25.8%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.2%-13.2%
Q1 2026-16.6%-33.2%-44.0%
Q3 2025-17.0%-20.0%-32.3%
Q1 2025+1.9%-18.7%-59.3%
Q4 2024-2.6%-12.6%-59.2%
Q3 2024-3.0%-10.7%-28.2%
Q2 2024-14.9%-21.9%-62.8%
Q1 2024-1.9%-9.7%-47.9%
Q4 2023-8.7%-7.7%-18.1%
Q3 2023-15.2%-19.0%-52.5%
Q2 2023-25.8%-23.3%-51.6%
Q1 2023-5.0%-13.8%-16.1%
Q4 2022-0.7%-4.9%-17.9%
Q3 2022-21.0%-13.8%-26.1%
Q2 2022-10.7%-11.2%-32.7%
Q1 2022-8.3%-20.3%-3.1%
Q4 2021-2.1%-9.8%-0.9%
Q3 2021-0.7%+1.7%-22.1%
Q2 2021+18.1%+26.4%+12.4%
Q1 2021+8.4%+10.7%+14.9%
Q4 2020+37.4%+27.0%+62.6%
Q3 2020+13.2%+12.5%+129.0%
Q2 2020-2.1%-4.6%-19.3%
Q1 2020-3.6%-9.9%-7.7%
Q4 2019-5.8%+2.2%-7.7%
Q3 2019-3.6%-10.2%-40.8%
Q2 2019+3.1%+18.9%+31.4%
Q1 2019-11.4%-18.6%-18.1%
Q4 2018+1.6%+7.0%+1.1%
Q3 2018+3.1%+0.8%+9.8%
Q2 2018-1.6%+2.8%+2.4%
Q1 2018+6.8%+23.2%+7.7%
Q4 2017+11.3%+5.8%-10.1%
Q3 2017+0.0%+5.8%+28.6%
Q2 2017-7.9%-10.5%+4.6%
Q1 2017+6.9%+6.9%+40.5%
Q4 2016+0.5%+3.7%+44.4%
Q3 2016+0.8%-0.8%-21.2%
Q2 2016+2.2%+10.9%+17.4%
Q1 2016+2.6%
Q4 2015-4.8%
Q3 2015-9.3%
Q2 2015-7.0%
Q1 2015+21.5%
Q4 2014-16.5%
Q4 2013-16.5%
Q3 2014-9.2%
Q2 2014-1.4%
Q1 2014-2.9%
Q3 2013+4.2%
Q2 2013-18.5%
Q1 2013+0.0%
Q4 2012-9.1%
Q3 2012-20.0%
Q2 2012-7.1%
Q1 2012+1.5%
Q4 2011+1.5%
Q3 2011+0.0%
Q2 2011+0.0%
Q4 2010
Q3 2010
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro